Alan Reyes Mondragón: Are We Entering the Post-Cisplatin Era in Bladder Cancer?

Alan Reyes Mondragón, Profesor at TecSalud del Tecnológico de Monterrey, shared a post on LinkedIn:

“For ~20 years, the perioperative standard for muscle-invasive bladder cancer has been clear:
Cisplatin-based neoadjuvant chemotherapy to cystectomy.
But EV-304 / KEYNOTE-B15 may change that.

At ASCO GU 2026, enfortumab vedotin + pembrolizumab improved event-free survival, overall survival, and pCR vs gemcitabine/cisplatin – even in cisplatin-eligible patients.

A platinum-free regimen outperforming the platinum standard.
Are we witnessing the beginning of the post-cisplatin era in bladder cancer?
Exciting times in urothelial oncology.

Read further.”

Other articles about Bladder Cancer.